Treatment of pain with opioid-based therapy is challenging due to inherent medication risks and increasing pressures of the opioid epidemic. Methadone has a unique role in pain management in comparison to other opioid agonists given its complex pharmacologic, pharmacokinetic, and pharmacodynamic profiles.  Significant drug interactions and patient safety concerns must be well understood in order to optimize methadone’s use.  Buprenorphine, a partial agonist at the µ-opioid receptor and an antagonist at the κ-opioid receptor with high affinity for both receptors, is advantageous in some patients with pain who have risk factors that make treatment with other opioid options unfavorable. This session will improve knowledge and skills pertaining to methadone and buprenorphine use.